Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
5
×
boston blog main
boston top stories
life sciences
national blog main
alnylam pharmaceuticals
rna interference
clinical trials
drugs
national top stories
aminolevulinic acid
fda
givosiran
harvard pilgrim health care
institute for clinical and economic review
new york blog main
onpattro
patisiran
san francisco blog main
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
alexion pharmaceuticals
alnylam pharmaceutials
amy schulman
andreas klein
anna greka
arrowhead pharmaceuticals
barry greene
biotech
boehringer ingelheim
car-t
caron jacobson
cigall kadoch
craig mello
dan ollendorf
deals
dicerna pharmaceuticals
What
interference
5
×
rna
rnai
alnylam
drug
medicine
ago
fda
gene
market
medicines
pharmaceuticals
second
seek
speedy
abandoning
approval
approves
aren’t
baggage
car
cells
cleared
companies
cuts
cutting
data
deal
development
dicerna
edge
ema
employ
europe
experiments
far
follows
free
gets
harmful
Language
Current search:
interference
×
boston
×
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”